Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03607656 | The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer(CHANGE) | completed | Phase 2 / Phase 3 | 270 | Shanghai University of Traditional Chinese MedicineOTHER | 1 |
| Dec 18, 2023 |
| clinicaltrials |
| NCT01515748 | Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer(PRODIGY) | completed | Phase 3 | 530 | SanofiINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections | withdrawn | Phase 3 | 0 | Antonios LikourezosOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02178956 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer(BRIGHTER) | completed | Phase 3 | 714 | Sumitomo Pharma America, Inc.INDUSTRY | 22 | Nov 15, 2023 | clinicaltrials |
| NCT01678027 | Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication | active not recruiting | Phase 3 | 1,838 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06115629 | Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial(SARONG-II) | not yet recruiting | Phase 3 | 952 | University of Dublin, Trinity CollegeOTHER | 5 | Nov 3, 2023 | clinicaltrials |
| NCT04219332 | Randomized Controlled Trial on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection | unknown | Phase 3 | 266 | Fujian Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02338518 | Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients(SVOSA) | unknown | Phase 3 | 297 | Jinling Hospital, ChinaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04611997 | IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 240 | Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05264896 | Perioperative FLOT vs Adjuvant XELOX for CA Stomach | recruiting | Phase 3 | 110 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05914610 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 3 | 100 | Fujian Medical UniversityOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT03745170 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | completed | Phase 3 | 650 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05325528 | Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases | unknown | Phase 2 / Phase 3 | 40 | Zhejiang UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04222114 | Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis | unknown | Phase 3 | 282 | LintonPharm Co.,Ltd.INDUSTRY | 3 | Jan 31, 2023 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05610332 | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | not yet recruiting | Phase 3 | 216 | Fujian Medical UniversityOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02661971 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)(RAMSES/FLOT7) | completed | Phase 2 / Phase 3 | 180 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT04139135 | A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | unknown | Phase 3 | 642 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05230771 | Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT05270824 | Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT04787354 | Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) | recruiting | Phase 3 | 976 | Hallym University Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT03801668 | Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | unknown | Phase 3 | 294 | Huazhong University of Science and TechnologyOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer(SOLAR) | completed | Phase 3 | 711 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 2 | Dec 20, 2021 | clinicaltrials |
| NCT04859582 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02395640 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | completed | Phase 3 | 438 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT02934464 | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers(ARMANI) | unknown | Phase 3 | 280 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | unknown | Phase 2 / Phase 3 | 60 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04997837 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | recruiting | Phase 3 | 433 | Fudan UniversityOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02158988 | Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis(GASTRIPEC) | completed | Phase 3 | 105 | Charite University, Berlin, GermanyOTHER | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04358354 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 3 | 388 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04384601 | Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | not yet recruiting | Phase 3 | 246 | Ruijin HospitalOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT03196791 | Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient | completed | Phase 3 | 196 | Korea University Anam HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT03961867 | Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma | unknown | Phase 3 | 440 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04393584 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma(RusGCG-01) | unknown | Phase 2 / Phase 3 | 538 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00002883 | Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus | completed | Phase 3 | 250 | UNICANCEROTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04486651 | HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 3 | 560 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT04483076 | Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer(RESONANCE-II) | recruiting | Phase 3 | 524 | Chinese PLA General HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT04677673 | Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients(RJGC-Senile) | not yet recruiting | Phase 2 / Phase 3 | 232 | BIRENDRA KUMAR SAHOTHER | 0 | Dec 21, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Dec 19, 2023source: clinicaltrials